EN
TR
GBA1 variants and Parkinson’s Disease: A dual approach combining clinical data and literature review
Abstract
Aim: The GBA1 (ENSG00000177628) gene, a key susceptibility gene in Parkinson’s disease (PD) and closely linked to Gaucher disease, has garnered significant research attention over the past two decades. Mutations in GBA1 are associated with an elevated risk of developing PD. This study aims to elucidate genetic mutations related to PD in a cohort of patients undergoing clinical exome analysis. We aimed to investigate the clinical and genetic profiles of patients with Parkinson’s disease, focusing on GBA1 gene mutations and additional neurodegenerative-related genetic alterations.
Materials and Methods: Fourteen patients with a preliminary diagnosis of Parkinson's disease underwent clinical exome analysis. The research included genetic testing to identify variants of uncertain significance, likely pathogenic mutations, and pathogenic mutations in the GBA1 gene. Further genetic alterations were evaluated in patients with positive GBA1 mutation results.
Results: 14 out of 177 diagnosed individuals had GBA1 mutations. The group had 8 men and 6 women with a mean onset age of 53.7 years. Tremor, stiffness, bradykinesia, hypomimia, and postural instability predominated. Dopamine agonists were often administered for symptoms. Disorders like depression, anxiety, hypercholesterolemia, and diabetes were frequent. GBA1 gene study found many missense variants, with the p.Asn409Ser (N370S) mutation being the most common. Four individuals also had mutations in EIF4G1, APP, and SLC20A2, demonstrating a complex genetic landscape affecting PD.
Conclusion: Our research highlights PD's genetic diversity, particularly GBA1 mutations' role in disease onset and progression. Additional genetic variants may worsen PD symptoms. Further research is needed on these mutations' pathogenicity and consequences on patient care.
Keywords
Destekleyen Kurum
None
Etik Beyan
Etik kurul onayı alınmıştır.
Teşekkür
Hasta ve yakınlarına teşekkürler.
Kaynakça
- Savitt JM, Dawson VL, Dawson TM. Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest. 2006;116(7):1744-54.
- Lesage S, Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet. 2009;18(R1):R48-59.
- Halperin A, Elstein D, Zimran A. Increased incidence of Parkinson disease among relatives of patients with Gaucher disease. Blood Cells Mol Dis. 2006;36(3):426-8.
- Alcalay RN, Levy OA, Waters CC, Fahn S, Ford B, Kuo SH, et al. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. Brain. 2015;138(Pt 9):2648-58.
- Beavan M, Schapira AH. Glucocerebrosidase Gene Mutation and Preclinical Markers of Parkinson Disease-Reply. JAMA Neurol. 2015;72(6):724.
- Macerollo A. Glucocerebrosidase Gene Mutation and Preclinical Markers of Parkinson Disease. JAMA Neurol. 2015;72(6):723-4.
- Chatterjee D, Krainc D. Mechanisms of Glucocerebrosidase Dysfunction in Parkinson's Disease. J Mol Biol. 2023;435(12):168023.
- Huang Y, Yu F, Feng L, Wang X. The Association between E326K of GBA and the Risk of Parkinson's Disease. Parkinsons Dis. 2018;2018:1048084.
Ayrıntılar
Birincil Dil
İngilizce
Konular
Tıbbi Genetik (Kanser Genetiği hariç) , Nöroloji ve Nöromüsküler Hastalıklar
Bölüm
Araştırma Makalesi
Yayımlanma Tarihi
10 Haziran 2025
Gönderilme Tarihi
12 Kasım 2024
Kabul Tarihi
27 Ocak 2025
Yayımlandığı Sayı
Yıl 1970 Cilt: 64 Sayı: 2